Management of vascular risk in people with multiple sclerosis at the time of diagnosis in England: A population-based study

被引:7
作者
Palladino, Raffaele [1 ,2 ,6 ]
Marrie, Ruth Ann [3 ]
Majeed, Azeem [1 ]
Chataway, Jeremy [4 ,5 ]
机构
[1] Imperial Coll London, Sch Publ Hlth, Dept Primary Care & Publ Hlth, London, England
[2] Univ Naples Federico II, Dept Publ Hlth, Naples, Italy
[3] Univ Manitoba, Max Rady Coll Med, Rady Fac Hlth Sci, Dept Med & Community Hlth Sci, Winnipeg, MB, Canada
[4] UCL, UCL Queen Sq Inst Neurol, Fac Brain Sci, Queen Sq Multiple Sclerosis Ctr,Dept Neuroinflamma, London, England
[5] Univ Coll London Hosp, Natl Inst Hlth Res, Biomed Res Ctr, London, England
[6] Imperial Coll London, Sch Publ Hlth, Dept Primary Care & Publ Hlth, London W6 8RP, England
关键词
Multiple sclerosis; epidemiology; vascular management; diabetes; hypertension; BMI; HIGH-DOSE SIMVASTATIN; PRIMARY-CARE; SEX-DIFFERENCES; MS-STAT; COMORBIDITY; HYPERTENSION; DISABILITY; FRAILTY; DISEASE;
D O I
10.1177/13524585231164296
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Vascular management in People with Multiple Sclerosis (PwMS) is important given the higher vascular burden than the general population, associated with increased disability and mortality. Objectives: We assessed differences in the prevalence of type 2 diabetes and hypertension; and the use of antidiabetic, antihypertensive and lipid-lowering medications at the time of the MS diagnosis. Methods: This is a population-based study including PwMS and matched controls between 1987 and 2018 in England. Results: We identified 12,251 PwMS and 72,572 matched controls. PwMS had a 30% increased prevalence of type 2 diabetes (95% confidence interval (CI) = 1.19, 1.42). Among those with type 2 diabetes, PwMS had a 56% lower prevalence of antidiabetic usage (95% CI = 0.33, 0.58). Prevalence of hypertension was 6% greater in PwMS (95% CI = 1.05, 1.06), but in those with hypertension, usage of antihypertensive was 66% lower in PwMS (95% CI = 0.28, 0.42) than controls. Treatment with lipid-lowering medications was 63% lower in PwMS (95% CI = 0.54, 0.74). PwMS had a 0.4-mm Hg lower systolic blood pressure (95% CI = -0.60, -0.13). 3.8% of PwMS were frail. Conclusion: At the time of diagnosis, PwMS have an increased prevalence of vascular risk factors, including hypertension and diabetes though paradoxically, there is poorer treatment. Clinical guidelines supporting appropriate vascular assessment and management in PwMS should be developed.
引用
收藏
页码:671 / 679
页数:9
相关论文
共 38 条
  • [1] Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study
    Barnett, Karen
    Mercer, Stewart W.
    Norbury, Michael
    Watt, Graham
    Wyke, Sally
    Guthrie, Bruce
    [J]. LANCET, 2012, 380 (9836) : 37 - 43
  • [2] Bassi S, 2020, NEUROLOGY, V94
  • [3] Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation
    Belvisi, Daniele
    Canevelli, Marco
    Baione, Viola
    Buscarinu, Maria Chiara
    Pellicciari, Giulia
    Fantozzi, Roberta
    Creta, Armando
    Cecchi, Gianluca
    Cola, Gaia
    Nicoletti, Carolina Gabri
    Cortese, Antonio
    De Giglio, Laura
    Tartaglia, Matteo
    Crisafulli, Sebastiano Giuseppe
    Bruno, Giuseppe
    Ferraro, Elisabetta
    Marfia, Girolama Alessandra
    Centonze, Diego
    Salvetti, Marco
    Conte, Antonella
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (12) : 1939 - 1947
  • [4] Frailty and co-morbidity predict first hospitalisation after heart failure diagnosis in primary care: population-based observational study in England
    Bottle, Alex
    Kim, Dani
    Hayhoe, Benedict
    Majeed, Azeem
    Aylin, Paul
    Clegg, Andrew
    Cowie, Martin R.
    [J]. AGE AND AGEING, 2019, 48 (03) : 347 - 354
  • [5] Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial
    Chan, Dennis
    Binks, Sophie
    Nicholas, Jennifer M.
    Frost, Chris
    Cardoso, M. Jorge
    Ourselin, Sebastien
    Wilkie, David
    Nicholas, Richard
    Chataway, Jeremy
    [J]. LANCET NEUROLOGY, 2017, 16 (08) : 591 - 600
  • [6] Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial
    Chataway, Jeremy
    Schuerer, Nadine
    Alsanousi, Ali
    Chan, Dennis
    MacManus, David
    Hunter, Kelvin
    Anderson, Val
    Bangham, Charles R. M.
    Clegg, Shona
    Nielsen, Casper
    Fox, Nick C.
    Wilkie, David
    Nicholas, Jennifer M.
    Calder, Virginia L.
    Greenwood, John
    Frost, Chris
    Nicholas, Richard
    [J]. LANCET, 2014, 383 (9936) : 2213 - 2221
  • [7] Development and validation of an electronic frailty index using routine primary care electronic health record data
    Clegg, Andrew
    Bates, Chris
    Young, John
    Ryan, Ronan
    Nichols, Linda
    Teale, Elizabeth Ann
    Mohammed, Mohammed A.
    Parry, John
    Marshall, Tom
    [J]. AGE AND AGEING, 2016, 45 (03) : 353 - 360
  • [8] CPRD, About us
  • [9] Validation of an algorithm for identifying MS cases in administrative health claims datasets
    Culpepper, William J.
    Marrie, Ruth Ann
    Langer-Gould, Annette
    Wallin, Mitchell T.
    Campbell, Jonathan D.
    Nelson, Lorene M.
    Kaye, Wendy E.
    Wagner, Laurie
    Tremlett, Helen
    Chen, Lie H.
    Leung, Stella
    Evans, Charity
    Yao, Shenzhen
    LaRocca, Nicholas G.
    [J]. NEUROLOGY, 2019, 92 (10) : E1016 - E1028
  • [10] Evans C., 2021, BMJ OPEN, V11